Cardiovascular and metabolic toxicity of abiraterone in castration-resistant prostate cancer: Post-marketing experience.

e17043Background: Abiraterone improves survival in metastatic castration-resistant prostate cancer (mCRPC) but may result in the development or worsening of comorbid conditions. We assessed the cou...